JASON HASS: Open Payments
NPI 1831176486 · SUPERIOR, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$389 in 22 payments from 11 companies in 2025. Trend: 2023 $562 · 2024 $702 · 2025 $389
Food & beverage: $389
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $61 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
| Gilead Sciences, Inc. | 3 | $49 |
| Abbott Laboratories | 2 | $44 |
| ABBVIE INC. | 2 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $37 |
| AstraZeneca Pharmaceuticals LP | 1 | $35 |
| Amgen Inc. | 2 | $29 |
| Exact Sciences Corporation | 1 | $17 |
| Lundbeck LLC | 1 | $15 |
Products named: REXULTI, Ozempic, FREESTYLE LIBRE 3, CAPLYTA, IMFINZI, EVENITY, VRAYLAR, Cologuard Collection Kit.
Industry payments across NE — which companies pay providers there.
